A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation

BMC Clinical Pharmacology

Arno Hazekamp²  Hendrika H van Hell¹  Samantha J Broyd¹  Nadia Solowij¹ 

[1] School of Psychology, Ψ-P3: Centre for Psychophysics, Psychophysiology and Psychopharmacology and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW 2522, Australia;Department of Plant Metabolomics, Faculty of Science, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands

关键词: Intrapulmonary Administration;    Vaporisation;    ∆⁹-Tetrahydrocannabinol (THC);    Cannabidiol (CBD);    Cannabinoids;   

Others  :  1084665
DOI  :  10.1186/2050-6511-15-58

 received in 2014-05-19, accepted in 2014-09-30,  发布年份 2014

【 摘 要 】

Background

Significant interest has emerged in the therapeutic and interactive effects of different cannabinoids. Cannabidiol (CBD) has been shown to have anxiolytic and antipsychotic effects with high doses administered orally. We report a series of studies conducted to determine the vaporisation efficiency of high doses of CBD, alone and in combination with ∆⁹-tetrahydrocannabinol (THC), to achieve faster onset effects in experimental and clinical trials and emulate smoked cannabis.

Methods

Purified THC and CBD (40 mg/ml and 100 mg/ml respectively) were loaded onto a liquid absorbing pad in a Volcano® vaporiser, vaporised and the vapours quantitatively analysed. Preliminary studies determined 200 mg CBD to be the highest dose effectively vaporised at 230°C, yielding an availability of approximately 40% in the vapour phase. Six confirmatory studies examined the quantity of each compound delivered when 200 mg or 4 mg CBD was loaded together with 8 mg of THC.

Results

THC showed 55% availability when vaporised alone or with low dose CBD, while large variation in the availability of high dose CBD impacted upon the availability of THC when co-administered, with each compound affecting the vaporisation efficiency of the other in a dynamic and dose-dependent manner. We describe optimised protocols that enable delivery of 160 mg CBD through vaporisation.

Conclusions

While THC administration by vaporisation is increasingly adopted in experimental studies, often with oral predosing with CBD to examine interactive effects, no studies to date have reported the administration of CBD by vaporisation. We report the detailed methodology aimed at optimising the efficiency of delivery of therapeutic doses of CBD, alone and in combination with THC, by vaporisation. These protocols provide a technical advance that may inform methodology for clinical trials in humans, especially for examining interactions between THC and CBD and for therapeutic applications of CBD.

Trial registration

Current Controlled Trials ISRCTN24109245

【 授权许可】

   
2014 Solowij et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH: The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
• [2]Zuardi AW: Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatria 2008, 30:271-280.
• [3]Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D: Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012, 2:e94.
• [4]Morgan CJ, Curran HV: Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008, 192:306-307.
• [5]Morgan CJ, Schafer G, Freeman TP, Curran HV: Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study. Br J Psychiatry 2010, 197:285-290.
• [6]Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O’Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK: Opposite effects of ∆-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774.
• [7]Schoedel KA, Harrison SJ: Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols): potentials and limitations for psychosis research. Curr Pharm Des 2012, 18:5008-5014.
• [8]Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M: Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983, 34:352-363.
• [9]Grotenhermen F: Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinetics 2003, 42:327-360.
• [10]Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L: Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986, 38:21-43.
• [11]Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R: Evaluation of a vaporizing device (Volcano®) for the pulmonary delivery of tetrahydrocannabinol. J Pharm Sci 2006, 95:1308-1317.
• [12]Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JCME, Verpoorte R, Pinquier JL, Cohen AF, van Gerven JMA: Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacology 2008, 22:707-716.
• [13]Bossong MG, van Berckel BNM, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JMA, Ramsey NF, Lammertsma AA, Kahn RS: Δ9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34:759-766.
• [14]van Hell HH, Bossong MG, Jager G, Kahn RS, Ramsey NF: Pharmacological imaging of the cannabinoid system (PhICS): towards understanding the role of the brain endocannabinoid system in human cognition. Int J Methods Psychiatr Res 2011, 20:10-27.
• [15]Hazekamp A, Simons R, Peltenburg-Looman A, Sengers M, Van Zweden R, Verpoorte R: Preparative isolation of cannabinoids from Cannabis sativa by centrifugal partition chromatography. J Liquid Chromat Rel Technol 2004, 27:2421-2439.
• [16]Hazekamp A, Choi YH, Verpoorte R: Quantitative analysis of cannabinoids from Cannabis sativa using 1H-NMR. Chem Pharm Bull 2004, 52:718-721.
• [17]Romano LL, Hazekamp A: Cannabis Oil: chemical evaluation of an upcoming cannabis-based medicine. Cannabinoids 2013, 1:1-11.
• [18]Solowij N: Vulnerability markers in the association between cannabis and schizophrenia: a randomised controlled trial of acute cannabinoid administration. Current Controlled Trials 2012, 5:5. http://www.controlled-trials.com/ISRCTN24109245 webcite
• [19]Potter DJ, Clark P, Brown MB: Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J Forensic Sci 2008, 53:90-94.
• [20]Swift W, Wong A, Li KM, Arnold JC, McGregor IS: Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile. PLoS One 2013, 8:e70052.
• [21]Bergamaschi MM, Costa Queiroz RH, Nisihara Chagas MH, de Gomes Oliveira DC, de Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JEC, Zuardi AW, Crippa JAS: Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011, 36:1219-1226.
• [22]Klein C, Karanges E, Spiro A, Wong A, Spencer J, Huynh T, Gunasekaran N, Karl T, Long LE, Huang XF, Liu K, Arnold JC, McGregor IS: Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology 2011, 218:443-457.
• [23]Varvel SA, Wiley JL, Yang R, Bridgen DT, Long K, Lichtman AH, Martin BR: Interactions between THC and cannabidiol in mouse models of cannabinoid activity. Psychopharmacology 2006, 186:226-234.
• [24]Zuardi AW, Hallak JE, Crippa JA: Interaction between cannabidiol (CBD) and ∆(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. Psychopharmacology 2012, 219:247-249.